ArticleCirculation2008
Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle.
Article in Circulation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Review
- Adenosine AInternational journal of molecular sciences · 2024Review
- The different effects of four adenosine receptors in liver fibrosis.Frontiers in pharmacology · 2024Article
- Adenosine signaling as target in cardiovascular pharmacology.Current opinion in pharmacology · 2023Review
- Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction.Frontiers in pharmacology · 2021Review
- Adenosine and the Cardiovascular System: The Good and the Bad.Journal of clinical medicine · 2020Review
- Review
- Adenosine kinase attenuates cardiomyocyte microtubule stabilization and protects against pressure overload-induced hypertrophy and LV dysfunction.Journal of molecular and cellular cardiology · 2019Article
- Effects of milrinone on inflammatory response-related gene expressions in cultured rat cardiomyocytes.Journal of biomedical research · 2018Article
- Targeting Adenosine Receptors for the Treatment of Cardiac Fibrosis.Frontiers in pharmacology · 2017Review
- Genetic Abrogation of Adenosine A3 Receptor Prevents Uninephrectomy and High Salt-Induced Hypertension.Journal of the American Heart Association · 2016Article
- Adenosine A3 Receptor: A promising therapeutic target in cardiovascular disease.Current cardiology reviews · 2016Review
- Beneficial and detrimental role of adenosine signaling in diseases and therapy.Journal of applied physiology (Bethesda, Md. : 1985) · 2015Review
- Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2.Hypertension (Dallas, Tex. : 1979) · 2014Article
- Cardioprotective effects of adenosine within the border and remote areas of myocardial infarction.EJNMMI research · 2013Article
- Adenosine kinase: exploitation for therapeutic gain.Pharmacological reviews · 2013Review
- Induced overexpression of Na(+)/Ca(2+) exchanger does not aggravate myocardial dysfunction induced by transverse aortic constriction.Journal of cardiac failure · 2013Article
- Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease.Hypertension (Dallas, Tex. : 1979) · 2012Article
- Cardioprotection of controlled and cardiac-specific over-expression of A(2A)-adenosine receptor in the pressure overload.PloS one · 2012Article
- AMP activated protein kinase-α2 regulates expression of estrogen-related receptor-α, a metabolic transcription factor related to heart failure development.Hypertension (Dallas, Tex. : 1979) · 2011Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEndogenous adenosine can protect the overloaded heart against the development of hypertrophy and heart failure, but the contribution of A(1) receptors (A(1)R) and A(3) receptors (A(3)R) is not known. METHODS AND
resultsTo test the hypothesis that A(1)R and A(3)R can protect the heart against systolic overload, we exposed A(3)R gene-deficient (A(3)R knockout [KO]) mice and A(1)R KO mice to transverse aortic constriction (TAC). Contrary to our hypothesis, A(3)R KO attenuated 5-week TAC-induced left ventricular hypertrophy (ratio of ventricular mass/body weight increased to 7.6+/-0.3 mg/g in wild-type mice compared with 6.3+/-0.4 mg/g in KO mice), fibrosis, and dysfunction (left ventricular ejection fraction decreased to 43+/-2.5% and 55+/-4.2% in wild-type and KO mice, respectively). A(3)R KO also attenuated the TAC-induced increases of myocardial atrial natriuretic peptide and the oxidative stress markers 3'-nitrotyrosine and 4-hydroxynonenal. In contrast, A(1)R KO increased TAC-induced mortality but did not alter ventricular hypertrophy or dysfunction compared with wild-type mice. In mice in which extracellular adenosine production was impaired by CD73 KO, TAC caused greater hypertrophy and dysfunction and increased myocardial 3'-nitrotyrosine. In neonatal rat cardiomyocytes induced to hypertrophy with phenylephrine, the adenosine analogue 2-chloroadenosine reduced cell area, protein synthesis, atrial natriuretic peptide, and 3'-nitrotyrosine. Antagonism of A(3)R significantly potentiated the antihypertrophic effects of 2-chloroadenosine.
conclusionsAdenosine exerts protective effects on the overloaded heart, but the A(3)R acts counter to the protective effect of adenosine. The data suggest that selective attenuation of A(3)R activity might be a novel approach to treat pressure overload-induced left ventricular hypertrophy and dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.